Prasol Chemicals Ltd Q1 FY2027 Concall Summary

Key Takeaways

• IPO quarter with a geopolitical windfall: Revenue grew 35.7% YoY to ₹433.6 crores, but ₹25 crores of the gross margin expansion came from an inventory gain as acetone prices spiked on West Asia supply disruptions, not from operating leverage alone.
• Guidance strips out the luck: Management guided FY27 revenue of ₹1,550–1,650 crores and EBITDA of ₹240–250 crores, explicitly excluding the Q1 inventory and forex gains, betting on volume and mix over price.
• Mahad has turned the corner: The troubled site moved from 13% utilization in FY24 to 60%+ and is now sustainably profitable, with a clear path to 70%+ by year-end and fresh land acquired for expansion.
• The pipeline is deep but distant: 40 R&D products, 13 commercialized in three years, an antibacterial drug 6 months out, and a mining chemical approved in the US, yet the bulk of Phase 1 capex revenue lands over two years and Phase 2 is still in site-prep stage.
• What to watch next quarter: Whether the guided margin normalization from 37.9% gross margin toward 30–32% is orderly or sharp as acetone prices cool, and any quantification of the Phase 1 capex split between Mahad and Khopoli.

The Q1 Windfall: Inventory Gain, Not Structural Margin

• Acetone price spike drove the beat: The West Asia conflict and Strait of Hormuz disruptions caused a sharp increase in crude oil and petrochemical prices; acetone, as a petrochemical derivative, saw sharp price increases, and inventory procured at lower prices was carried into the rising price environment, producing higher realizations.
• ₹25 crores quantified: Management pegged the positive impact on gross profit from the sharp increase in average selling price at ₹25 crores, and stated plainly that the company does not speculate on raw material pricing: the gain was circumstantial, arising because the company routinely stocks up raw materials from January–February for April onwards, and the war broke out in late February.
• Underlying volume was mid-single digit: Volume grew in the mid-single digit range while demand across all sectors remained strong, so the top-line surge was overwhelmingly price-led.
• Supply chain held through disruption: Diversified sourcing across geographies and global stock points in Rotterdam, China, and the United States kept product flowing; exports stayed at 27% of revenue despite some Africa/Middle East shipments being affected and substituted by increased volumes to Europe.

Nishith Rajnikant Shah: "We do not speculate in raw material, period. We buy raw materials based on our calculation, based on our need. We happen to be at a sweet spot, we got advantage thereof, which we have shown but we do not speculate on raw material pricing as a rule."

Mahad Turnaround: From Distress to Growth Platform

• Utilization climbed from 13% to 60%+: The Mahad site went through a difficult phase with COVID-related disruptions, agrochemical destocking, and a temporary shutdown in FY24; since restarting, significant investment in process safety and controls lifted utilization from about 13% in FY24 to 44% in FY26, and now past 60%.
• Now sustainably profitable: Management confirmed the site is both PBT and EBITDA positive, though it declined to share the exact Q1 EBITDA contribution when asked.
• Path to 70%+ by year-end: Existing products across all plants are expected to cross 70%+ utilization by the end of this year, and the Mahad site specifically is targeted to reach 70%+ toward year-end.
• Land bank expanded for brownfield growth: Less than a month ago, the company bought another 10 acres at Mahad, all in a single row, bringing the surplus to 20 acres at Mahad plus 10–12 acres at Khopoli; the adjoining land purchase allows sharing of engineering team, works manager, admin, safety, utilities, and ETP, so investment matures over 3–4 years with improving ROCE versus a greenfield.

Nishith Rajnikant Shah: "I see it as a much better -- I call it the New Bombay compared to Khopoli site, which I call it Old Bombay because we started with four acres and bought half acre, one acre, two acres as what our pockets could afford. Here, we have bought in 10-acre slabs and we have a perfect rectangular, very well designed, and I see Mahad as a growing this."

The R&D Engine: Pipeline Breadth, Long Conversion Cycles

• 40 products in the pipeline: Roughly 25–30 are forward integration of existing products, and about 25 are new chemistry including waste-to-product initiatives; management expects 15–20% to convert to commercialized products down the line.
• 13 products commercialized in three years: These span mining chemicals, agro intermediates, lubricant additives, and construction emulsifiers, demonstrating the model of developing customer-specific tweaks to existing molecules.
• Antibacterial drug is the nearest catalyst: R&D is complete, samples have been given to a multinational and approved, an NDA has been signed, and mechanical completion is expected by January with trial runs taking 60–90 days; commercial production is expected in the coming year, with expected volume of more than 100 tons a month to start, and management believes they will have a cost-competitive edge as the only one using this process.
• Mining chemical cleared a US gate: The product was approved in the US by one of the best labs, but results are expected in the coming two to three years as the initiative is in its initial phase.
• Application lab being built: A dedicated 4,000 sq ft application testing lab for lubricant additives, construction, and mining chemicals is under construction with an investment of ₹15–20 crores, ready in the next five to six months.
• Multi-purpose R&D plant now operational: Built as of March, it enables in-house experimentation with fixed bed reactors and capability at various temperatures and pressures, replacing previously outsourced job work to improve speed and quality of sample delivery.
• Waste-to-product chemistry in development: The company is working with institutions to convert waste streams into input products for new chemistry; an example given was waste disposed at ₹10 converted to a product sold at ₹80 with ₹15–20 conversion cost.

Nishith Rajnikant Shah: "The applications keep on coming with small tweak to the existing molecule that we are doing, and that's how -- and that's why we believe we are loved by our end user, and we love working with them because the larger companies do not have the patience to work and tweak this 0.2, 0.1 requirements, and Prasol is a company which patiently works looking at the long-term goal, not at a immediate, what it will give me next year."

Capex: Two Phases, Two Years, Limited Visibility on Split

• Phase 1: ₹250–300 crores over two years: Funded through internal accruals and potentially some additional debt if required; at peak utilization, this investment is expected to generate about ₹500–550 crores of revenue.
• Phase 1 timeline is staggered: All 10–12 projects to be completed and installed across the next 12–18 months from today; projects will be at varying stages, some at 80–90% complete, others at 20%, 50%, or still on the drawing board.
• Phase 2: another ₹250–300 crores: Targeted at new R&D products with better margins, but product identification, site preparation, and regulatory approvals are still in progress; more details promised in coming quarters.
• Khopoli vs Mahad split undisclosed: When asked for the breakup of the 60,000-ton capacity addition between the two sites, management said it had not brought that data to the table and would provide it in second-half guidelines.
• Storage investment at Khopoli: More than ₹25 crores to be invested in the next year in adjoining land for additional acetone storage with floating-roof tanks.
• Lubricant debottlenecking is near-term: Existing capacity to increase by 50% to 70% through agitator design changes, with results expected in the next two to three months, before March.
• Capacity expansion trigger is utilization-led: Management's stated philosophy is to expand only when plants reach 75–80% utilization and when clients have definite growth plans; in the coming year and a half to two years, the company is looking at expanding every product being made.

Nishith Shah: "Once we reach about 75% to 85% of the installed capacity, and we have a sense from the end users regarding the growth at their end where they're going to use our product, we go ahead and start building the next stream."

Business Model: Backward Integration and Mix Shift

• The playbook is import, capture share, then manufacture: Trading (distribution) share was ~30% seven to eight years ago, is now ~18%, and is targeted to drop to ~10% in five years; the policy is to import a product, capture 50%+ market share, then backward-integrate into manufacturing, moving EBITDA from 5–6% to ~15%.
• Revenue mix is balanced: Acetone-based products contribute ~40%, phosphorus-based ~40%, and other specialty chemicals ~20% in Q1 FY27.
• Intent to move up the derivative chain: Management intends to go for primary, secondary, and tertiary derivatives in coming years; higher-value products will drive revenue growth even with single-digit volume growth, which is why the company declined to provide volume guidance, stating volume alone may not be the right metric.
• Customer stickiness is structural: The majority of customers have never left and continue to grow with the company over time; the precision work of narrowing a product's impurity range from ±0.2% to 0.05% improves the customer's yields and deepens trust.
• Global distribution footprint expanding: Consignment stock points are operational in Houston, Rotterdam, and Shanghai, with plans to expand more depots for just-in-time delivery; the company already has REACH registration in six or seven products and plans to extend to more volumes.
• IPO proceeds fully deployed: The fresh issue raised gross proceeds of ₹80 crores; ₹60 crores allocated to debt repayment has been utilized, and ₹16.4 crores went to general corporate purposes, in line with the offer document.

Guidance & Commitments

Key Metrics